EUVIMEDEUVIMED entdecken
Vergleichsstudie

Comparative Kidney Uptake of Nanobody-Based PET Tracers Labeled with Various Fluorine-18-Labeled Prosthetic Groups

Colleen P Olkowski, Falguni Basuli, Bruna Fernandes, Behnaz Ghaemi, Jianfeng Shi, Hongwei H Zhang, Joshua M Farber, Freddy E Escorcia, Peter L Choyke, Orit Jacobson iD

Molecular Pharmaceutics · 2025

DOI: 10.1021/acs.molpharmaceut.4c01101 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Molecular Pharmaceutics, 2025. Verfasst von Colleen P Olkowski und 9 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Imaging Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, United Stat…. Hauptthemen laut MEDLINE: Fluorine Radioisotopes, Single-Domain Antibodies, Kidney, Positron-Emission Tomography. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 28 Literaturangaben. Gefördert von: National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Nanobodies, or single-domain antibody fragments, are promising candidates for molecular imaging due to their small size, rapid tissue penetration, and high target specificity. However, a significant challenge in their use is high renal uptake and retention, which can limit the therapeutic efficacy and complicate image interpretation. This study compares five different fluorine-18-labeled prosthetic groups for nanobodies, aiming to optimize pharmacokinetics and minimize kidney retention while maintaining tumor targeting. Using an epidermal growth factor receptor (EGFR) targeting nanobody as a model, two labeling approaches were evaluated; direct labeling of RESCA (with and without polyethylene glycol (PEG))-conjugated nanobody using Al[18F]F and indirect labeling using ([18F]F-fluoropyridine ([18F]F-FPy)-based prosthetic groups (site-specific and nonsite-specific). Labeled nanobodies were characterized in vitro for binding affinity and cell uptake with in vivo behavior assessed in EGFR + A431 tumor-bearing mice using PET imaging and biodistribution studies. Labeling with Al[18F]F showed high renal retention, which was partially mitigated by PEGylation. However, PEGylation also led to a decreased tumor uptake, particularly with longer PEG chains. Labeling using [18F]F-FPy prosthetic groups exhibited the most favorable pharmacokinetics, with rapid renal clearance and minimal kidney retention while maintaining high tumor uptake. These constructs showed excellent tumor-to-background contrast as early as 1 h postinjection. The study confirms that the selection of the prosthetic group significantly impacts the in vivo behavior of nanobodies, particularly regarding kidney accumulation. [18F]F-FPy-based prosthetic groups show the most promising results, with high tumor and minimal kidney uptake. Robust production of [18F]F-FPy on Sep-Pak is adaptable to clinical translation. Moreover, the potential substitution of 18F with therapeutic radioisotopes such as 131I or 211At could expand the application of these nanobodies from diagnostics to targeted radionuclide therapy while maintaining a low kidney exposure. These findings have important implications for optimizing nanobody-based radiopharmaceuticals for molecular imaging and targeted radionuclide therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Fluorine RadioisotopesSingle-Domain AntibodiesKidneyPositron-Emission TomographyAnimalsMiceHumansTissue DistributionCell Line, TumorRadiopharmaceuticalsErbB ReceptorsFemalePolyethylene GlycolsMice, Nude

Stichwörter der Autor:innen

A431 xenograftEGFRPETSortase-Afluorine-18nanobody

Substanzen

Fluorine RadioisotopesSingle-Domain AntibodiesFluorine-18RadiopharmaceuticalsErbB ReceptorsPolyethylene Glycols

Autor:innen und Institutionen

  • Molecular Imaging Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, United States.
  • Chemistry and Synthesis Center, National Heart, Lung, and Blood Institute, National Institutes of Health, Rockville, Maryland 20850, United States.
  • Laboratory of Molecular Immunology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, United States.
  • Radiation Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, United States.

ORCID-Profile: Orit Jacobson

Förderung

  • National Cancer Institute

Zitieren

APA

Olkowski, C. P., Basuli, F., Fernandes, B., Ghaemi, B., Shi, J., Zhang, H. H., Farber, J. M., Escorcia, F. E., Choyke, P. L., & Jacobson, O. (2025). Comparative Kidney Uptake of Nanobody-Based PET Tracers Labeled with Various Fluorine-18-Labeled Prosthetic Groups. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.4c01101

Vancouver

Olkowski CP, Basuli F, Fernandes B, Ghaemi B, Shi J, Zhang HH, et al. Comparative Kidney Uptake of Nanobody-Based PET Tracers Labeled with Various Fluorine-18-Labeled Prosthetic Groups. Molecular Pharmaceutics. 2025. doi:10.1021/acs.molpharmaceut.4c01101

BibTeX
@article{Olkowski2025,
  author = {Olkowski, Colleen P and Basuli, Falguni and Fernandes, Bruna and Ghaemi, Behnaz and Shi, Jianfeng and Zhang, Hongwei H and Farber, Joshua M and Escorcia, Freddy E and Choyke, Peter L and Jacobson, Orit},
  title = {Comparative Kidney Uptake of Nanobody-Based PET Tracers Labeled with Various Fluorine-18-Labeled Prosthetic Groups},
  journal = {Molecular Pharmaceutics},
  year = {2025},
  doi = {10.1021/acs.molpharmaceut.4c01101}
}
Kostenlos starten →